View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Aug. 07, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Caladrius Biosciences, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		9,725,442

Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 22,725,383	$ 29,163,200
Restricted cash	0	5,004,789
Marketable securities	27,597,303	25,916,681
Prepaid and other current assets	1,228,898	1,312,503
Total current assets	51,551,584	61,397,173
Property and equipment, net	98,123	256,905
Other assets	442,806	1,721,604
Total assets	52,092,513	63,375,682
Current Liabilities
Accounts payable	505,665	1,343,089
Accrued liabilities	5,299,075	7,810,948
Notes payable, current	23,289	159,180
Total current liabilities	5,828,029	9,313,217
Other long-term liabilities	2,797,933	3,872,679
Total liabilities	8,625,962	13,185,896
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2018 and December 31, 2017, respectively	100	100
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,735,361 and 9,483,911 shares at June 30, 2018 and December 31, 2017, respectively	9,735	9,484
Additional paid-in capital	435,337,922	433,044,209
Treasury stock, at cost; 11,080 shares at June 30, 2018 and December 31, 2017	(707,637)	(707,637)
Accumulated deficit	(390,869,059)	(381,810,109)
Accumulated other comprehensive loss	(31,091)	(27,978)
Total Caladrius Biosciences, Inc. stockholders' equity	43,739,970	50,508,069
Noncontrolling interests	(273,419)	(318,283)
Total equity	43,466,551	50,189,786
Liabilities and Equity, Total	$ 52,092,513	$ 63,375,682

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	1	1
Preferred stock, par value (in usd per share)	$ 0.01	$ 0.01
Preferred stock, shares designated	825,000	825,000
Preferred stock, shares issued	10,000	10,000
Preferred stock, shares outstanding	10,000	10,000
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	9,735,361	9,483,911
Common stock, shares, outstanding	9,735,361	9,483,911
Treasury stock (shares)	11,080	11,080

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating Expenses:
Research and development	$ 2,122,610	$ 4,277,783	$ 4,384,850	$ 8,003,915
General and administrative	2,146,570	3,432,534	5,043,014	6,138,928
Total operating expenses	4,269,180	7,710,317	9,427,864	14,142,843
Operating loss	(4,269,180)	(7,710,317)	(9,427,864)	(14,142,843)
Other income (expense):
Other income (expense), net	193,654	4,828	371,192	(39,567)
Interest expense	(1,666)	(204,484)	(4,961)	(363,412)
Total other income (expense), net	191,988	(199,656)	366,231	(402,979)
Loss from continuing operations before benefit from income taxes and noncontrolling interests	(4,077,192)	(7,909,973)	(9,061,633)	(14,545,822)
Benefit from income taxes	0	(5,887,543)	0	(5,887,543)
Net loss from continuing operations	(4,077,192)	(2,022,430)	(9,061,633)	(8,658,279)
Discontinued operations - net of taxes	0	40,487,438	0	37,329,963
Net (loss) income	(4,077,192)	38,465,008	(9,061,633)	28,671,684
Less - net loss from continuing operations attributable to noncontrolling interests	(821)	(54,676)	(2,683)	(119,342)
Less - net loss from discontinued operations attributable to noncontrolling interests	0	(199,325)	0	(568,156)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	(4,076,371)	38,719,009	(9,058,950)	29,359,182
Amounts attributable to Caladrius Biosciences, Inc. common stockholders:
Loss from continuing operations	(4,076,371)	(1,967,754)	(9,058,950)	(8,538,937)
Discontinued operations - net of taxes	0	40,686,763	0	37,898,119
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,076,371)	$ 38,719,009	$ (9,058,950)	$ 29,359,182
Basic and diluted (loss) income per share
Continuing operations (in usd per share)	$ (0.42)	$ (0.22)	$ (0.95)	$ (0.99)
Discontinued operations (in usd per share)	0.00	4.56	0.00	4.38
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.42)	$ 4.34	$ (0.95)	$ 3.39
Weighted average common shares outstanding:
Basic and diluted shares	9,591,958	8,926,783	9,577,195	8,657,334

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (4,077,192)	$ 38,465,008	$ (9,061,633)	$ 28,671,684
Available for sale securities - net unrealized income (loss)	27,633	(57,860)	(3,113)	(57,860)
Total other comprehensive income (loss)	27,633	(57,860)	(3,113)	(57,860)
Comprehensive (loss) income	(4,049,559)	38,407,148	(9,064,746)	28,613,824
Comprehensive loss attributable to noncontrolling interests	(821)	(254,001)	(2,683)	(687,498)
Comprehensive (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,048,738)	$ 38,661,149	$ (9,062,063)	$ 29,301,322

Consolidated Statements of Equity - USD ($)	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2016			10,000	8,205,790
Beginning Balance at Dec. 31, 2016	$ 4,066,480	$ 4,883,909	$ 100	$ 8,206	$ 410,372,049	$ 0	$ (404,788,809)	$ (707,637)	$ (817,429)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	28,671,684	29,359,182					29,359,182		(687,498)
Unrealized loss on marketable securities	(57,860)	(57,860)				(57,860)
Share-based compensation (in shares)				54,545
Share-based compensation	2,350,652	2,350,652		$ 55	2,350,597
Net proceeds from issuance of common stock (in shares)				648,432
Net proceeds from issuance of common stock	3,278,632	3,278,632		$ 648	3,277,984
Proceeds from option exercises (in shares)				3,835
Proceeds from option exercises	13,576	13,576		$ 4	13,572
Elimination of equity associated with PCT sale	(3,686,526)	0							(3,686,526)
Conversion of redeemable securities	19,400,000	14,733,908			14,733,908				4,666,092
Change in ownership in subsidiary	0	(141,180)			(141,180)				141,180
Ending Balance (shares) at Jun. 30, 2017			10,000	8,912,602
Ending Balance at Jun. 30, 2017	54,036,638	54,420,819	$ 100	$ 8,913	430,606,930	(57,860)	(375,429,627)	(707,637)	(384,181)
Beginning Balance (shares) at Dec. 31, 2016			10,000	8,205,790
Beginning Balance at Dec. 31, 2016	4,066,480	4,883,909	$ 100	$ 8,206	410,372,049	0	(404,788,809)	(707,637)	(817,429)
Ending Balance (shares) at Dec. 31, 2017			10,000	9,483,911
Ending Balance at Dec. 31, 2017	50,189,786	50,508,069	$ 100	$ 9,484	433,044,209	(27,978)	(381,810,109)	(707,637)	(318,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(9,061,633)	(9,058,950)					(9,058,950)		(2,683)
Unrealized loss on marketable securities	(3,113)	(3,113)				(3,113)
Share-based compensation (in shares)				126,759
Share-based compensation	1,712,064	1,712,064		$ 127	1,711,937
Net proceeds from issuance of common stock (in shares)				50,070
Net proceeds from issuance of common stock	287,554	287,554		$ 49	287,505
Proceeds from option exercises (in shares)				74,621
Proceeds from option exercises	341,893	341,893		$ 75	341,818
Change in ownership in subsidiary	0	(47,547)			(47,547)				47,547
Ending Balance (shares) at Jun. 30, 2018			10,000	9,735,361
Ending Balance at Jun. 30, 2018	$ 43,466,551	$ 43,739,970	$ 100	$ 9,735	$ 435,337,922	$ (31,091)	$ (390,869,059)	$ (707,637)	$ (273,419)

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net (loss) income	$ (9,061,633)	$ 28,671,684
Income from discontinued operations	0	(37,329,963)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	2,114,596	1,819,382
Depreciation and amortization	169,434	193,845
(Gain) loss on disposal of assets	(1,378,763)	175,793
Accretion on marketable securities	155,292	39,175
Changes in operating assets and liabilities:
Prepaid and other current assets	83,605	422,656
Other assets	157,561	179,763
Due to/from PCT	0	(1,231,258)
Accounts payable, accrued liabilities and other liabilities	(4,424,043)	(2,879,408)
Net cash used in operating activities - continuing operations	(12,183,951)	(9,938,331)
Net cash used in operating activities	0	(638,069)
Net cash used in operating activities	(12,183,951)	(10,576,400)
Cash flows from investing activities:
Purchase of marketable securities	(38,321,027)	(36,421,971)
Sale of marketable securities	36,482,000	0
Proceeds from CFC device sale	2,500,000	0
Net proceeds from PCT sale	0	70,264,395
Net cash sold in PCT sale	0	(6,727,263)
Acquisition of property and equipment	(10,652)	(97,052)
Net cash provided by investing activities - continuing operations	650,321	27,018,109
Net cash used in investing activities - discontinued operations	0	(188,794)
Net cash provided by investing activities	650,321	26,829,315
Cash flows from financing activities:
Proceeds from exercise of options	341,893	13,576
Tax withholding payments on net share settlement equity awards	(402,532)	(357,665)
Net proceeds from issuance of common stock	287,554	3,278,632
Repayment of long-term debt	0	(5,651,354)
Proceeds from notes payable	0	400,998
Repayment of notes payable	(135,891)	(522,313)
Net cash provided by (used in) financing activities - continuing operations	91,024	(2,838,126)
Net cash used in financing activities - discontinued operations	0	(74,231)
Net cash provided by (used in) financing activities	91,024	(2,912,357)
Net (decrease) increase in cash, cash equivalents and restricted cash	(11,442,606)	13,340,558
Cash, cash equivalents and restricted cash at beginning of period - continuing operations	34,167,989	7,076,651
Cash and cash equivalents at beginning of period - discontinued operations	0	7,628,357
Cash, cash equivalents and restricted cash at end of period	22,725,383	28,045,566
Cash paid during the period for:
Interest	4,961	697,544
Taxes	$ 0	$ 0

The Business	6 Months Ended
The Business	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Business	The Business Overview Caladrius Biosciences, Inc. (“we,” “us,” "our," “Caladrius” or the “Company”) is a company developing cellular therapeutics to treat select cardiovascular and autoimmune diseases. We leverage specialized development expertise to advance our therapies through development with the aim of eventually obtaining market authorization and commercializing, either alone or with partners, and providing treatment options to patients suffering from life-threatening medical conditions. Our product candidates include autologous CD34 cell-based therapies for ischemic repair that are in phase 2 of clinical development as well as an autologous, ex vivo expanded and activated, polyclonal regulatory T cell ("Treg") therapy completing a phase 2 study targeting recent-onset type 1 diabetes mellitus ("T1D") in children aged 8-17. We also have acquired the rights to data and regulatory filings for a CD34-based cell therapy program for refractory angina, which had advanced to phase 3 under the previous investigational new drug application (“IND”) holder. We have designated this program CLBS14-RfA. Ischemic Repair (CD34 Cell Technology) Our CD34 cell technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Through the administration of CD34 cells, we seek to promote the development and formation of new blood vessels and thereby increase blood flow to the impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34 cell technology, including critical limb ischemia ("CLI"), coronary microvascular dysfunction ("CMD") and refractory angina ("RfA"). Published reports in Circulation Cardiovascular Interventions, Atherosclerosis, Stem Cells and Circulation Journal, provide preliminary evidence that CD34 cell therapy is safe and can exert significant therapeutic effects in patients with CLI, a condition in which blood flow to the legs is severely impaired, causing pain and non-healing ulcers and, ultimately, potentially resulting in the need for amputation. Our Clinical Trial Notification for a pivotal Phase 2 trial investigating our product candidate in CLI, CLBS12, was submitted to the Japanese Pharmaceutical and Medical Device Agency ("PMDA") and was cleared to proceed. The protocol design was agreed to with PMDA, the study was opened for enrollment in December 2017 and treatment of the first patient was announced in March 2018. Based on our discussions with the PMDA, we expect that a successful outcome of this trial will qualify CLBS12 for consideration of early conditional approval in Japan, thereby effectively making our phase 2 trial a registration trial. In addition, Japan’s Ministry of Health, Labour and Welfare (“MHLW”) recently assigned CLBS12 “SAKIGAKE” designation (a Japanese regulatory status similar to "breakthrough" designation awarded by the U.S. Food and Drug Administration ("FDA") in the USA) reflecting its expectation of “prominent effectiveness” based on data of mechanism of action from non-clinical and early phase clinical trials. The SAKIGAKE Designation System promotes research and development in Japan, driving early practical application for innovative pharmaceutical products, medical devices and regenerative medicines. As a designated therapy under the system, CLBS12 should have the benefits of prioritized consultation, a dedicated review system to support the development and review process, as well as reduced review time from the normal 12 months down to 6 months. In anticipation of a successful trial outcome and the possibility of conditional approval, we continue to seek a local partner for CLBS12 in Japan. We also have acquired the rights to data and regulatory filings for a CD34-based cell therapy program for refractory angina, which had advanced to phase 3 under the previous investigational new drug application (“IND”) holder. We have designated this program CLBS14-RfA and recently reactivated the IND with the FDA. On June 19, 2018, the Company announced that it had received regenerative medicine advanced therapy (“RMAT”) designation from the FDA for CLBS14-RfA for the treatment of refractory angina. This designation affords the Company an opportunity to work with the FDA to more rapidly and efficiently advance the development of this therapeutic candidate in an indication that has no effective treatment options and high morbidity. Furthermore, we submitted grant applications in an effort to seek non-dilutive financing to investigate the CD34 technology for additional clinical indications in the United States. In October 2017 we announced the award of a $1.9 million grant from the National Institutes of Health to support a clinical study of CD34 cells in patients with coronary microvascular dysfunction. The first patient has been enrolled in this study of CLBS14-CMD. Immunomodulation (Treg Technology) We are developing strategically, through the utilization of our core development expertise, a product candidate (CLBS03) that has the potential to be an innovative therapy for T1D. This therapy is based on a proprietary platform technology for immunomodulation. We have selected, as an initial target, the unmet medical need of patients who are newly diagnosed with T1D, most of whom will be under the age of 18. This program is based on the use of Tregs to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg number and function. Tregs are a natural part of the human immune system and regulate the activity of effector T cells, the cells that are responsible for protecting the body from pathogens and foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by effector T cells. In autoimmune disease, however, it is thought that deficient Treg activity and numbers permit the effector T cells to attack the body's own beneficial cells. In the case of T1D, the beta cells in the pancreas are attacked, thereby reducing and/or eliminating over time the patient's ability to produce insulin. Insulin is necessary to regulate sugar metabolism and maintain proper sugar levels in the blood. Inconsistent or unnatural insulin levels can lead to many complications, including blindness, vascular disease and, if no insulin supplement is provided, even death. There are currently no curative treatments for TID, only lifelong insulin therapy, which often does not prevent serious co-morbidities. Two Phase 1 clinical trials of Treg technology in T1D, taken together demonstrated safety and tolerance, feasibility of manufacturing, an implied durability of effect as well as an early indication of potential therapeutic effect through the preservation of beta cell function. In the first quarter of 2016, we commenced patient enrollment in the first of two cohorts in The Sanford Project: T-Rex Study, a Phase 2 prospective, randomized, placebo-controlled, double-blind clinical trial (the "TRex Study") to evaluate the safety and efficacy of CLBS03 in adolescents with recent onset TID. We entered into a strategic collaboration with Sanford Research to support the execution of this trial. Sanford Research is a U.S.-based non-profit research organization that supports an emerging translational research center focused on finding a cure for T1D. CLBS03 has been granted Fast Track and orphan drug designations from the U.S. Food and Drug Administration ("FDA") as well as Advanced Therapeutic Medicinal Product ("ATMP") classification from the European Medicines Agency ("EMA"). In October 2016, we received a satisfactory safety evaluation by our independent Data Safety Monitoring Board based on safety data then available from the first 19 patients enrolled in the trial. A subsequent interim analysis was conducted after approximately 50% of patients reached the six-month follow-up milestone, the results of which were publicly released in March 2018 that the therapy continued to be well tolerated and was deemed non-futile for therapeutic effect. In January 2018, we announced completion of enrollment (110 patients) of the TRex Study. In February 2017, the California Institute for Regenerative Medicine ("CIRM") awarded us funds of up to $12.2 million to support the T-Rex Study. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. In March 2018, CIRM calculated the precise amount of the funding award as $8.6 million, based on the actual number of subjects enrolled in California. We have received total funding of $7.9 million through June 30, 2018. Additional Out-licensing Opportunities Our broad intellectual property portfolio of cell therapy assets includes notable programs available for out-licensing in order to continue their clinical development. These include additional indications for our Treg product and additional indications for our CD34 cell technology. Our current long-term strategy focuses on advancing our therapies through development with the aim of eventually obtaining market authorization and commercializing, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones. Discontinued Operations On May 18, 2017, we completed the previously announced sale of our remaining 80.1% membership interest in PCT, LLC, a Caladrius company ("PCT") to Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to the Interest Purchase Agreement (the "Purchase Agreement") dated as of March 16, 2017, by and among us, PCT and Hitachi (the "2017 Hitachi Transaction"), for $75.0 million in cash plus an additional cash adjustment of $4.4 million based on PCT’s cash and outstanding indebtedness as of the closing date and a potential future milestone payment (see Note 3). The sale of PCT represented a strategic shift that has had a major effect on our operations, and therefore, all periods presented were adjusted to reflect PCT as discontinued operations. PCT is now known as Hitachi Chemical Advanced Therapeutic Systems ("HCATS"). Basis of Presentation The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of June 30, 2018, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2017 and 2016 included in our 2017 Form 10-K. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and income taxes. Accordingly, actual results could differ from those estimates and assumptions. An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application. Principles of Consolidation The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates, as well as the operations of our former subsidiaries PCT, LLC, a Caladrius company, NeoStem Family Storage, LLC, and PCT Allendale, LLC entities (collectively the "PCT Segment") through May 18, 2017, representing the date which these entities were sold to Hitachi (see Note 3). The PCT Segment is reported in discontinued operations. All intercompany activities have been eliminated in consolidation, except for intercompany activities between Caladrius and the PCT Segment, which are reported without intercompany eliminations in continuing operations and discontinued operations, respectively.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2017 Form 10-K. There were no changes to these policies during the three and six months ended June 30, 2018. Concentration of Risks We are subject to credit risk from our portfolio of cash, cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return. Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. Income Taxes The Company recognizes (a) the amount of taxes payable or refundable for the current year and (b) deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The Tax Cuts and Jobs Act (“the Act”) was enacted on December 22, 2017. The income tax effects of changes in tax laws are recognized in the period when enacted. The Act provides for significant tax law changes and modifications with varying effective dates, which include reducing the U.S. federal corporate income tax rate from 35% to 21%, creating a territorial tax system (with a one-time mandatory repatriation tax on previously deferred foreign earnings), and allowing for immediate capital expensing of certain qualified property acquired and placed in service after September 27, 2017 and before January 1, 2023. In response to the enactment of the Act in late 2017, the U.S. Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address situations where the accounting is incomplete for certain income tax effects of the Tax Act upon issuance of an entity’s financial statements for the reporting period in which the Tax Act was enacted. Under SAB 118, a company may record provisional amounts during a measurement period for specific income tax effects of the Tax Act for which the accounting is incomplete but a reasonable estimate can be determined, and when unable to determine a reasonable estimate for any income tax effects, report provisional amounts in the first reporting period in which a reasonable estimate can be determined. The Company continues to evaluate the accounting for uncertainty in tax positions at the end of each reporting period. The guidance requires companies to recognize in their financial statements the impact of a tax position if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The position ascertained inherently requires judgment and estimates by management. The Company recognizes interest and penalties as a component of income tax expense. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 was effective in first quarter of fiscal 2018. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard was effective on January 1, 2018. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard was effective on January 1, 2018 and the Company early adopted the standard in 2017, with all adjustments reflected as of the beginning of the fiscal years reported. In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In June 2018 the FASB issued ASU No. 2018-07, "Improvements to Nonemployee Share-Based Payment Accounting", which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. For public companies, the amendments are effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but no earlier than a company's adoption date of ASC 606. The Company is currently assessing the impact that adopting this new accounting guidance will have on its financial statements and footnote disclosures.

Collaboration and License Agreement

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

Collaboration and License Agreement

2016 Hitachi Transaction

On March 11, 2016, PCT entered into a global collaboration with Hitachi (the "2016 Hitachi Transaction"). This collaboration consisted of an equity investment in and a license agreement with PCT.

Under the equity investment agreement, Hitachi purchased a 19.9% membership interest in PCT for $19.4 million of which $15.0 million of proceeds was distributed to Caladrius from PCT and $4.4 million remained at PCT to be used for the continued expansion and improvements at PCT in support of commercial product launch readiness as well as for general corporate purposes.

PCT and Hitachi also entered into an exclusive license agreement for the acceleration of the creation of a global commercial cell therapy development and manufacturing expertise in Asia pursuant to which PCT received $5.6 million from Hitachi in 2016. PCT licensed certain cell therapy technology and know-how (including an exclusive license in Asia) and agreed to provide Hitachi with certain training and support. As additional consideration, Hitachi agreed to pay PCT royalties on contract revenue generated in Asia for a minimum of ten years. In connection with the 2017 Hitachi Transaction described below, this exclusive license agreement was terminated.

2017 Hitachi Transaction

On May 18, 2017, the Company sold its remaining 80.1% membership interest in PCT to Hitachi pursuant to the Purchase Agreement, dated as of March 16, 2017, by and among Caladrius PCT and Hitachi (the "2017 Hitachi Transaction"). The aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) $4.4 million, representing additional consideration based on PCT’s cash and outstanding indebtedness as of the closing date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in cumulative revenue (excluding clinical service reimbursables) (the “Milestone”) for the period from January 1, 2017 through December 31, 2018 (the “Milestone Period”).

Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the closing date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. The Escrow Amount was classified as restricted cash on the consolidated balance sheets as of December 31, 2017. In June 2018, the escrow agent disbursed to the Company the Escrow Amount in full. The Company also received the $4.4 million additional consideration payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the 2017 Hitachi Transaction, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% was paid in May 2018 on the one-year anniversary of the closing date.

Concurrent with the signing of the Purchase Agreement, on March 16, 2017, Caladrius entered into a Retention and Incentive Agreement with Robert A. Preti, a former Caladrius director and a co-founder and the President of PCT, (the “Retention Agreement”). The Retention Agreement superseded all prior agreements and understandings between Dr. Preti and Caladrius regarding the subject matter of the Retention Agreement. Among other things, the Retention Agreement provided:


•	Simultaneously with the closing of the 2017 Hitachi Transaction, Caladrius pay to Dr. Preti $1.9 million (the “First Retention Payment”).

•

As an incentive to remain employed with PCT and to use commercially reasonable efforts to cause PCT to maximize its overall performance and in particular to achieve the Milestone (but not contingent upon achieving the Milestone), Dr. Preti receive a lump-sum cash retention and incentive payment equal to $1.9 million for the period from the closing date of the 2017 Hitachi Transaction until the date one year after the date of the closing (the “Anniversary Date”), subject to Dr. Preti’s continued employment with PCT through the Anniversary Date (the “Second Retention Payment”). In May 2018, the Second Retention Payment was paid to Dr. Preti.


•	Dr. Preti is entitled to 5% of the Milestone if it is successfully earned.

Available-for-Sale-Securities

6 Months Ended

Jun. 30, 2018

Available-for-sale Securities [Abstract]

Available-for-Sale Securities

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	June 30, 2018									December 31, 2017
	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Corporate debt securities	$	34,276	$	—	$	(31	)	$	34,245	$	42,701	$	—	$	(28	)	$	42,673
Money market funds	5,730		—		—			5,730		9,212		—		—			9,212
Total	$	40,006	$	—	$	(31	)	$	39,975	$	51,913	$	—	$	(28	)	$	51,885

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	June 30, 2018		December 31, 2017
Cash and cash equivalents	$	12,378	$	25,968
Marketable securities	27,597		25,917
Total	$	39,975	$	51,885

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	June 30, 2018
	Amortized Cost		Estimated Fair Value
Less than one year	$	40,006	$	39,975
Greater than one year	—		—
Total	$	40,006	$	39,975

Loss Per Share

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Loss Per Share

For the three and six months ended June 30, 2018 and 2017, the Company incurred net losses from continuing operations and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At June 30, 2018 and 2017, the Company excluded the following potentially dilutive securities:



	June 30,
	2018	2017
Stock Options	1,073,216	1,119,580
Warrants	48,654	285,462
Restricted Stock Units	45,248	10,260

Fair Value Measurements

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Measurements

The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of June 30, 2018, and December 31, 2017 (in thousands).



	June 30, 2018								December 31, 2017
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	27,597	$	—	$	27,597	$	—	$	25,917	$	—	$	25,917
	$	—	$	27,597	$	—	$	27,597	$	—	$	25,917	$	—	$	25,917

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accrued Liabilities

6 Months Ended

Jun. 30, 2018

Accrued Liabilities [Abstract]

Accrued Liabilities

Accrued liabilities as of June 30, 2018 and December 31, 2017 were as follows (in thousands):



	June 30, 2018		December 31, 2017
Salaries, employee benefits and related taxes	$	1,415	$	1,389
Retention payments	—		2,233
CIRM upfront funding - current	2,583		2,446
Other	1,301		1,743
Total	$	5,299	$	7,811

Debt	6 Months Ended
Debt	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt	Debt Notes Payable The Company's notes payable relate to certain equipment financings, require monthly payments, and mature within one year.

Stockholders' Equity

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Stockholders' Equity

Equity Issuances

September 2016 Private Placement

In September 2016, the Company entered into Securities Purchase Agreements with certain accredited investors with whom it had a substantive, pre-existing relationship, including certain existing stockholders, for the sale by the Company of its common stock, at a purchase price of $4.72 per share. The investments were placed in two tranches whereby (i) $6.6 million was received and 1.4 million shares of common stock were issued in 2016 upon an initial closing, and (ii) $4.4 million was received and 0.9 million shares of common stock were issued in 2017, which was subject to certain closing conditions, including the enrollment of 70 subjects in the Company’s Phase 2 CLBS03 clinical trial, in a second closing.

Aspire Purchase Agreement

In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that, subject to certain terms and conditions and Nasdaq rules, Aspire Capital was committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 1.1 million shares, unless stockholder approval was obtained or certain minimum sale price levels were reached) of the Company's common stock over a 24-month term. The Company issued 319,776 shares under the Purchase Agreement for gross proceeds of $1.5 million, which Purchase Agreement expired in November 2017.

Common Stock Sales Agreement

In February 2018, the Company entered into a common stock sales agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("HCW"), as sales agent, in connection with an “at the market offering” under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $12 million (limited to a maximum of approximately 2,790,697 shares). Subject to the terms and conditions of the Sales Agreement, HCW will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares from time to time, based upon the Company's instructions, including any price, time or size limits specified by the Company. The Company has provided HCW with customary indemnification rights, and HCW will be entitled to a commission at a fixed commission rate equal to 3.0% of the gross proceeds per share sold. In addition, pursuant to the terms of the Sales Agreement, the Company agreed to reimburse HCW $50,000 for legal fees incurred in connection with entering into the Sales Agreement, plus up to $2,500 per calendar quarter in fees for other filing requirements arising from the transactions contemplated by the Sales Agreement. Sales of the shares, if any, under the sales agreement may be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the shares, and may at any time suspend sales under the Sales Agreement or terminate the Sales Agreement. The Sales Agreement will terminate upon the sale of all of the shares under the Sales Agreement unless terminated earlier by either party as permitted under the Sales Agreement. During the six months ended June 30, 2018, the Company issued 34,215 shares of common stock under the Sales Agreement for net proceeds of $0.2 million.

In August 2018, the Company entered into an amendment to the Sales Agreement to reflect that the shares will be issued pursuant to a Registration Statement on Form S-3 that was declared effective in August 2018 and that replaced the Company’s previously effective shelf registration statement. In connection with the amendment, the number of shares of common stock that may be sold pursuant to the Sales Agreement was increased from an aggregate offering amount of $12,000,000 to $25,000,000 (see Note 15).

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2018:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2017	1,072,499		$	33.50	4.76	$	0.1	209,818		$	53.20	0.95	$	—

Changes during the period:
Granted	144,310		3.80					—		—
Exercised	(74,622	)	4.60					—		—
Forfeited	(3,030	)	3.80					—		—
Expired	(65,941	)	24.50					(161,164	)	50.30
Outstanding at June 30, 2018	1,073,216		$	31.50	5.42	$	1,237.5	48,654		$	59.84	2.95	$	17.4
Vested at June 30, 2018 or expected to vest in the future	1,061,160		$	31.80	5.37	$	1,205.7	48,654		$	59.84	2.95	$	17.4
Vested at June 30, 2018	963,497		$	34.60	4.95	$	950.5	48,654		$	59.84	2.95	$	17.4

Restricted Stock

During the six months ended June 30, 2018 and 2017, the Company issued restricted stock for services as follows ($ in thousands):



	Six Months Ended June 30,
	2018		2017
Number of restricted stock issued	127,688		132,726
Value of restricted stock issued	$	351	$	470

Share-Based Compensation

6 Months Ended

Jun. 30, 2018

Share-based Compensation [Abstract]

Share-Based Compensation

We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units. The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2018 and 2017 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Research and development	$	341	$	162	$	381	$	208
General and administrative	1,627		1,262		1,734		1,611
Discontinued operations	—		751		—		889
Total share-based compensation expense	$	1,968	$	2,175	$	2,115	$	2,708

The approval of the 2017 Hitachi Transaction (see Note 3) by our stockholders resulted in a change in control under our equity compensation plans (as defined in the 2009 Plan and the 2015 Equity Plan). Accordingly, all outstanding unvested equity awards were accelerated upon the closing date of the 2017 Hitachi Transaction, resulting in an acceleration of $1.9 million of equity compensation in the second quarter of 2017. In addition, in connection with the 2017 Hitachi Transaction, the Company agreed to extend the post-termination option exercise period for all PCT employees transitioning to Hitachi from 90 days to the earlier of (i) two years (May 18, 2019) or (ii) the date of the employees' termination from PCT. The post-termination option exercise period modification resulted in an additional expense of $0.3 million, which was recorded entirely during the three months ended June 30, 2017 and recorded in discontinued operations, since there were no future service requirements to receive the extended benefit.

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at June 30, 2018 were as follows (in thousands):



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	259	$	—
Expected weighted-average period in years of compensation cost to be recognized	2.19		0.00

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June 30, 2018 and 2017 were as follows (in thousands):



	Stock Options
	Six Months Ended June 30,
	2018		2017
Total fair value of shares vested	$	85	$	5,002
Weighted average estimated fair value of shares granted	$	2.41	$	1.72

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Research Funding	6 Months Ended
Research Funding	Jun. 30, 2018
Research Funding [Abstract]
Research Funding	Research Funding California Institute of Regenerative Medicine Grant Award In February 2017, CIRM awarded us funds of up to $12.2 million to support the T-Rex Study. The funding is based upon the achievement of certain milestones related to the proportion of subjects enrolled in California, as well as manufacturing and development costs incurred in California. In March 2018, CIRM calculated the precise amount of the funding award as $8.6 million, based on the actual number of subjects enrolled in California. The Company received $5.7 million in initial funding in May 2017, a $1.9 million milestone payment in December 2017, and $0.3 million progress payment in March 2018, of which the total will be amortized over the estimated award period through July 2020 as a reduction to the related research and development expenses. As of June 30, 2018, $2.6 million of the funding received is recorded in accrued liabilities, representing the amount expected to be recognized over the next 12 months, and $2.8 million of the funding received is recorded in other long-term liabilities. During the three and six months ended June 30, 2018, the Company amortized and recognized $0.6 million and $1.3 million in credits, respectively to research and development related to CIRM funds received. During the three and six months ended June 30, 2017, the Company amortized and recognized $0.3 million and $0.3 million in credits, respectively to research and development related to CIRM funds received.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time. As of December 31, 2017, the Company had approximately $210.3 million of Federal NOLs available to offset future taxable income expiring from 2030 through 2036. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur, there would be an annual limitation on the usage of the Company’s losses, which are available through 2036. The Company performed an analysis and determined that it has had ownership changes of greater than 50% over a 3 year testing period. The last ownership change was determined to be in 2015. Based on a market capitalization of $124.5 million and using an applicable federal rate of 2.5% the annual limitation would be approximately $3.0 million. Post change losses from June 3, 2015 through December 31, 2016 would not be subject to 382 limitations. Additionally the Company would be able to further increase NOL limitations by the realized built in gain on the sale of PCT in May of 2017. The Company applies the FASB’s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with certain tax positions as a component of income tax expense. As of June 30, 2018, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year. The Company completed the audit of its federal tax returns for the years 2012 and 2013 during the fourth quarter of 2016. The audit resulted in an adjustment to the Company's NOL carryforward. For years prior to 2014, the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of three to four years from date of filing. The Company ceased doing business in China in 2012. After 2012, the Company had no foreign tax filing obligations. The foreign returns filed for 2012 and prior are subject to examination for five years.

Discontinued Operations

6 Months Ended

Jun. 30, 2018

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

PCT Segment

On May 18, 2017, the Company sold its remaining 80.1% membership interest in PCT to Hitachi pursuant to the 2017 Hitachi Transaction (see Note 3). The aggregate purchase price to the Company consisted of (i) $75.0 million in cash, (ii) $4.4 million, representing additional consideration based on PCT’s cash and outstanding indebtedness as of the closing date, and (iii) a potential future milestone payment of $5.0 million if PCT achieves $125 million in cumulative revenue (excluding clinical service reimbursables) for the period from January 1, 2017 through December 31, 2018. The Company has determined that the fair value of the milestone payment as of the closing date was valued at zero.

Hitachi paid the Company $5.0 million in March 2017 as an advance payment pending shareholder approval of the transaction and other closing conditions. On the closing date, the Company received $65.0 million, with an additional $5.0 million of the purchase consideration (the "Escrow Amount") deposited into an escrow account to cover potential indemnification claims against Caladrius. In June 2018, the escrow agent disbursed to the Company the Escrow Amount in full. The Company also received the $4.4 million additional consideration payment in July 2017. The Company incurred approximately $6.9 million in transaction costs related to the 2017 Hitachi Transaction, including $4.3 million in retention payments to PCT employees, of which 50% was paid in June 2017, and the other 50% was paid in May 2018 on the one-year anniversary of the closing date.

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):



Fair value of consideration received	$	79,425
Transaction and retention costs	(6,919		)
Carrying value of segment non-controlling interest	3,687
	$	76,193
Less carrying amount of assets and liabilities sold:
Cash	$	6,727
Accounts receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	(2,278		)
Accrued liabilities	(2,927		)
Due from Caladrius	450
Unearned revenues	(10,529		)
Notes payable	(342		)
	$	24,449

Gain on sale of PCT Segment	$	51,744

The operations and cash flows of the PCT Segment were eliminated from ongoing operations with the sale of the Company's PCT Interest. The operating results of the PCT Segment for the three and six months ended June 30, 2017 were as follows (in thousands):



	Three Months Ended June 30, 2017			Six Months Ended June 30, 2017
Revenue	$	5,729		$	16,039
Cost of revenues	(5,268		)	(15,321		)
Research and development	(143		)	(257		)
Selling, general, and administrative	(8		)	(3,251		)
Other expense	(8		)	(16		)
Provision for income taxes	(11,559		)	(11,608		)
Gain on sale of PCT Segment	51,744			51,744
Income from discontinued operations	$	40,487		$	37,330

Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Lease Commitments

We lease facilities under various operating lease agreements in Basking Ridge, NJ, Rye Brook, NY, and Irvine, CA, of which certain have escalation clauses and renewal options. We also lease equipment under certain noncancelable operating leases. Our leases expire from time to time through 2021.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2018 are as follows (in thousands):



Years ended	Operating Leases
2018	$	448
2019	906
2020	829
2021	476
2022 and thereafter	130
Total minimum lease payments	$	2,789

Expense incurred under operating leases was approximately $0.2 million and $0.5 million for the three and six months ended June 30, 2018, respectively, and $0.4 million and $0.7 million for the three and six months ended June 30, 2017.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Amendment to the Common Stock Sales Agreement In August 2018, we entered into a First Amendment (the "Amendment") to the Sales Agreement, dated February 8, 2018 HCW, in connection with an “at the market offering” under which we may, from time to time, offer and sell shares of our common stock. Under the Amendment, we increased the aggregate offering price from $12,000,000 to $25,000,000. Shares sold under the Sales Agreement will be offered and sold pursuant to the Company’s Registration Statement on Form S-3, which was initially filed on July 24, 2018 and which was declared effective by the Securities and Exchange Commission on August 2, 2018 (Registration No. 333-226319). All other provisions of the Sales Agreement remain unchanged.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2018
Accounting Policies [Abstract]
Concentration of Risks	Concentration of Risks We are subject to credit risk from our portfolio of cash, cash equivalents and marketable securities. Under our investment policy, we limit amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of our investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.
Share-Based Compensation	Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model, which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.
Income Taxes	Income Taxes The Company recognizes (a) the amount of taxes payable or refundable for the current year and (b) deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The Tax Cuts and Jobs Act (“the Act”) was enacted on December 22, 2017. The income tax effects of changes in tax laws are recognized in the period when enacted. The Act provides for significant tax law changes and modifications with varying effective dates, which include reducing the U.S. federal corporate income tax rate from 35% to 21%, creating a territorial tax system (with a one-time mandatory repatriation tax on previously deferred foreign earnings), and allowing for immediate capital expensing of certain qualified property acquired and placed in service after September 27, 2017 and before January 1, 2023. In response to the enactment of the Act in late 2017, the U.S. Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address situations where the accounting is incomplete for certain income tax effects of the Tax Act upon issuance of an entity’s financial statements for the reporting period in which the Tax Act was enacted. Under SAB 118, a company may record provisional amounts during a measurement period for specific income tax effects of the Tax Act for which the accounting is incomplete but a reasonable estimate can be determined, and when unable to determine a reasonable estimate for any income tax effects, report provisional amounts in the first reporting period in which a reasonable estimate can be determined. The Company continues to evaluate the accounting for uncertainty in tax positions at the end of each reporting period. The guidance requires companies to recognize in their financial statements the impact of a tax position if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The position ascertained inherently requires judgment and estimates by management. The Company recognizes interest and penalties as a component of income tax expense.
Recently Issued Accounting Pronouncement	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This ASU requires that a lessee recognize lease assets and lease liabilities for those leases classified as operating leases. The guidance is effective for interim and annual periods beginning after December 15, 2018, and will be applied at the beginning of the earliest period presented using a modified retrospective approach. This ASU may have a material impact on the Company’s financial statements. The impact on the Company’s results of operations is currently being evaluated. The impact of the ASU is non-cash in nature and will not affect the Company’s cash position. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, accounting for forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for interim and annual periods beginning after December 15, 2016. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies how companies present and classify certain cash receipts and cash payments in the statement of cash flows where diversity in practice exists. ASU 2016-15 was effective in first quarter of fiscal 2018. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory. ASU 2016-16 requires the income tax consequences of intra-entity transfers of assets other than inventory to be recognized as current period income tax expense or benefit at the transaction date and removes the option to defer and amortize the consolidated tax consequences of intra-entity transfers. The new standard was effective on January 1, 2018. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The new standard was effective on January 1, 2018 and the Company early adopted the standard in 2017, with all adjustments reflected as of the beginning of the fiscal years reported. In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting," to provide clarity and reduce both diversity in practice and cost complexity when applying the guidance in Topic 718 to a change to the terms and conditions of a stock-based payment award. ASU 2017-09 also provides guidance about the types of changes to the terms or conditions of a share-based payment award that require an entity to apply modification accounting in accordance with Topic 718. For all entities, including emerging growth companies, the standard is effective for annual periods beginning after December 15, 2017, and for interim periods therein. Early adoption is permitted. The adoption of this new guidance did not have a material effect on the consolidated results of operations, cash flows, and financial position. In June 2018 the FASB issued ASU No. 2018-07, "Improvements to Nonemployee Share-Based Payment Accounting", which supersedes ASC 505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods and services from both employees and nonemployees. For public companies, the amendments are effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but no earlier than a company's adoption date of ASC 606. The Company is currently assessing the impact that adopting this new accounting guidance will have on its financial statements and footnote disclosures.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Available-for-Sale-Securities (Tables)

6 Months Ended

Jun. 30, 2018

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	June 30, 2018									December 31, 2017
	Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value		Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
Corporate debt securities	$	34,276	$	—	$	(31	)	$	34,245	$	42,701	$	—	$	(28	)	$	42,673
Money market funds	5,730		—		—			5,730		9,212		—		—			9,212
Total	$	40,006	$	—	$	(31	)	$	39,975	$	51,913	$	—	$	(28	)	$	51,885

Schedule of Marketable Securities



	June 30, 2018		December 31, 2017
Cash and cash equivalents	$	12,378	$	25,968
Marketable securities	27,597		25,917
Total	$	39,975	$	51,885

Investments Classified by Contractual Maturity Date

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	June 30, 2018
	Amortized Cost		Estimated Fair Value
Less than one year	$	40,006	$	39,975
Greater than one year	—		—
Total	$	40,006	$	39,975

Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

At June 30, 2018 and 2017, the Company excluded the following potentially dilutive securities:



	June 30,
	2018	2017
Stock Options	1,073,216	1,119,580
Warrants	48,654	285,462
Restricted Stock Units	45,248	10,260

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of Assets Measured at Fair Value on Recurring Basis



	June 30, 2018								December 31, 2017
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	27,597	$	—	$	27,597	$	—	$	25,917	$	—	$	25,917
	$	—	$	27,597	$	—	$	27,597	$	—	$	25,917	$	—	$	25,917

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2018

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities as of June 30, 2018 and December 31, 2017 were as follows (in thousands):



	June 30, 2018		December 31, 2017
Salaries, employee benefits and related taxes	$	1,415	$	1,389
Retention payments	—		2,233
CIRM upfront funding - current	2,583		2,446
Other	1,301		1,743
Total	$	5,299	$	7,811

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Schedule of Stock Option Activity

The following table summarizes the activity for stock options and warrants for the six months ended June 30, 2018:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2017	1,072,499		$	33.50	4.76	$	0.1	209,818		$	53.20	0.95	$	—

Changes during the period:
Granted	144,310		3.80					—		—
Exercised	(74,622	)	4.60					—		—
Forfeited	(3,030	)	3.80					—		—
Expired	(65,941	)	24.50					(161,164	)	50.30
Outstanding at June 30, 2018	1,073,216		$	31.50	5.42	$	1,237.5	48,654		$	59.84	2.95	$	17.4
Vested at June 30, 2018 or expected to vest in the future	1,061,160		$	31.80	5.37	$	1,205.7	48,654		$	59.84	2.95	$	17.4
Vested at June 30, 2018	963,497		$	34.60	4.95	$	950.5	48,654		$	59.84	2.95	$	17.4

Schedule of Restricted Stock

During the six months ended June 30, 2018 and 2017, the Company issued restricted stock for services as follows ($ in thousands):



	Six Months Ended June 30,
	2018		2017
Number of restricted stock issued	127,688		132,726
Value of restricted stock issued	$	351	$	470

Share-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Share-based Compensation [Abstract]

Schedule Share-based Compensation Expense

The following table summarizes the components of share-based compensation expense for the three and six months ended June 30, 2018 and 2017 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Research and development	$	341	$	162	$	381	$	208
General and administrative	1,627		1,262		1,734		1,611
Discontinued operations	—		751		—		889
Total share-based compensation expense	$	1,968	$	2,175	$	2,115	$	2,708

Schedule of Total Compensation Cost Related to Nonvested Awards



	Stock Options		Restricted Stock
Unrecognized compensation cost	$	259	$	—
Expected weighted-average period in years of compensation cost to be recognized	2.19		0.00

Schedule of Fair Value of Share-based Compensation Awards

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the six months ended June 30, 2018 and 2017 were as follows (in thousands):



	Stock Options
	Six Months Ended June 30,
	2018		2017
Total fair value of shares vested	$	85	$	5,002
Weighted average estimated fair value of shares granted	$	2.41	$	1.72

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2018

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

The Company recognized the following gain on the date of sale of its 80.1% interest in PCT (in thousands):



Fair value of consideration received	$	79,425
Transaction and retention costs	(6,919		)
Carrying value of segment non-controlling interest	3,687
	$	76,193
Less carrying amount of assets and liabilities sold:
Cash	$	6,727
Accounts receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	(2,278		)
Accrued liabilities	(2,927		)
Due from Caladrius	450
Unearned revenues	(10,529		)
Notes payable	(342		)
	$	24,449

Gain on sale of PCT Segment	$	51,744



	Three Months Ended June 30, 2017			Six Months Ended June 30, 2017
Revenue	$	5,729		$	16,039
Cost of revenues	(5,268		)	(15,321		)
Research and development	(143		)	(257		)
Selling, general, and administrative	(8		)	(3,251		)
Other expense	(8		)	(16		)
Provision for income taxes	(11,559		)	(11,608		)
Gain on sale of PCT Segment	51,744			51,744
Income from discontinued operations	$	40,487		$	37,330

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=84176398&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of June 30, 2018 are as follows (in thousands):



Years ended	Operating Leases
2018	$	448
2019	906
2020	829
2021	476
2022 and thereafter	130
Total minimum lease payments	$	2,789

The Business - Narrative (Details) $ in Millions	1 Months Ended					3 Months Ended	6 Months Ended
The Business - Narrative (Details) $ in Millions	Mar. 31, 2018 USD ($)	Jan. 31, 2018 patient	Dec. 31, 2017 USD ($)	Oct. 31, 2017 USD ($)	Oct. 31, 2016 patient	Mar. 31, 2016 cohort	Jun. 30, 2018 USD ($)	Feb. 28, 2017 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from grants	$ 0.3		$ 1.9				$ 7.9
Grants receivable	$ 8.6							$ 12.2
Ischemic Repair (CD34 Cell Technology) [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from grants				$ 1.9
The Sanford Project: T-Rex Study [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of cohorts \| cohort						2
Number of patients enrolled \| patient		110			19
Interim efficacy analysis, threshold (percent)					50.00%
Interim efficacy analysis, follow-up milestone period					6 months

The Business - Discontinued Operations (Details) - PCT Segment [Member] - Discontinued Operations [Member] $ in Millions	May 18, 2017 USD ($)
Subsidiary, Sale of Stock [Line Items]
Ownership interest (percent)	80.10%
Hitachi Chemical Co., LTD [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase agreement, additional consideration	$ 4.4
PCT Allendale, LLC [Member] \| Hitachi Chemical Co., LTD [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase agreement, aggregate purchase price	$ 75.0

Collaboration and License Agreement (Details) - USD ($) $ in Thousands				1 Months Ended				12 Months Ended
	May 18, 2018	May 18, 2017	Mar. 11, 2016	May 31, 2018	Jul. 31, 2017	Jun. 30, 2017	Mar. 31, 2017	May 18, 2018
Business Acquisition [Line Items]
Equity Method Investment, Ownership Percentage			19.90%
Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Recorded Unconditional Purchase Obligation			$ 19,400
Unrecorded Unconditional Purchase Obligation, Maximum Quantity			15,000
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Contract Receivable			$ 5,600
PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Purchase Obligation			$ 4,400
Minimum [Member] \| PCT Allendale, LLC [Member]
Business Acquisition [Line Items]
Length of Contract for Royalty Payments from Revenue Generated in Asia			10 years
Director [Member] \| Robert A. Preti [Member]
Business Acquisition [Line Items]
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, First Retention Payment		$ 1,900
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Second Retention Payment								$ 1,900
Related Party Transaction, Payment for Retention Agreement in Connection with Sale, Third Retention Payment, Percentage of Milestone Payment								5.00%
Discontinued Operations [Member] \| PCT Segment [Member]
Business Acquisition [Line Items]
Subsidiary, Ownership Interest by Parent		80.10%
Transaction Costs Related to Sale		$ 6,919
Payments to Employees		(4,300)
Retention Payments, First Retention Payment, Percent						50.00%
Retention Payments, Second Retention Payment, Percent	50.00%			50.00%
Discontinued Operations [Member] \| PCT Segment [Member] \| Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Purchase agreement, additional consideration		4,400
Purchase Agreement, Potential Future Milestone Payment		5,000
Cumulative Revenue Threshold for Receiving Milestone Payment		125,000
Proceeds From Licensing Agreements, Initial Payment							$ 5,000
Proceeds From Licensing Agreements, Closing Payments		65,000			$ 4,400
Proceeds From Licensing Agreements, Escrow Amount		5,000
Discontinued Operations [Member] \| PCT Segment [Member] \| PCT Allendale, LLC [Member] \| Hitachi Chemical Co., LTD [Member]
Business Acquisition [Line Items]
Purchase agreement, aggregate purchase price		$ 75,000

Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Schedule of Available-for-sale Securities [Line Items]
Cost	$ 40,006	$ 51,913
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(31)	(28)
Estimated Fair Value	39,975	51,885
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	5,730	9,212
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	5,730	9,212
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Cost	34,276	42,701
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(31)	(28)
Estimated Fair Value	$ 34,245	$ 42,673

Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Available-for-sale Securities [Abstract]
Cash and cash equivalents	$ 12,378,000	$ 25,968,000
Marketable securities	27,597,303	25,916,681
Total	$ 39,975,000	$ 51,885,000

Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Amortized Cost
Less than one year	$ 40,006
Greater than one year	0
Cost	40,006	$ 51,913
Estimated Fair Value
Less than one year	39,975
Greater than one year	0
Total estimated fair value	$ 39,975	$ 51,885

Loss Per Share (Details) - shares	6 Months Ended
Loss Per Share (Details) - shares	Jun. 30, 2018	Jun. 30, 2017
Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	1,073,216	1,119,580
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	48,654	285,462
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	45,248	10,260

Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	$ 27,597	$ 25,917
Assets, fair value disclosure	27,597	25,917
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	0	0
Assets, fair value disclosure	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	27,597	25,917
Assets, fair value disclosure	27,597	25,917
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities - available for sale	0	0
Assets, fair value disclosure	$ 0	$ 0

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References + Details

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 1,415	$ 1,389
Retention payments	0	2,233
CIRM upfront funding - current	2,583	2,446
Other	1,301	1,743
Total accrued liabilities	$ 5,299	$ 7,811

Debt (Details)	6 Months Ended
Debt (Details)	Jun. 30, 2018
Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument, term	1 year

Stockholders' Equity - Equity Issuances (Details)		1 Months Ended		6 Months Ended	12 Months Ended		25 Months Ended
Stockholders' Equity - Equity Issuances (Details)	Sep. 14, 2016 USD ($) clinical_trial_subject $ / shares	Feb. 28, 2018 USD ($) shares	Nov. 30, 2015 USD ($) shares	Jun. 30, 2018 USD ($) shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 shares	Nov. 30, 2017 shares	Aug. 09, 2018 USD ($)
Class of Stock [Line Items]
Shares issued, price (in usd per share) \| $ / shares	$ 4.72
Private Purchase Agreement [Member]
Class of Stock [Line Items]
Proceeds from issuance of common stock, initial closing	$ 6,600,000
Proceeds from issuance of common stock, second closing					$ 4,400,000
Stock issued (shares) \| shares					900,000	1,400,000
Number of subjects for Phase 2 CLBS03 clinical trial, second closing \| clinical_trial_subject	70
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Stock issued (shares) \| shares							319,776
Proceeds from issuance of stock			$ 1,500,000
Purchase commitment, remaining minimum amount committed			$ 30,000,000
Purchase commitment, maximum amount committed (shares) \| shares			1,100,000
Term of agreement in months			24 months
H.C. Wainwright Sales Agreement [Member]
Class of Stock [Line Items]
Stock issued (shares) \| shares				34,215
Proceeds from issuance of stock				$ 200,000
Aggregate offering amount authorized per agreement		$ 12,000,000		$ 12,000,000
Maximum number of shares authorized per agreement \| shares		2,790,697
Commission on gross proceeds due to third party (percent)		3.00%
Legal fees reimbursed to third party		$ 50,000
Quarterly filing fees payable, maximum		$ 2,500
Subsequent Event [Member] \| H.C. Wainwright Sales Agreement [Member]
Class of Stock [Line Items]
Aggregate offering amount authorized per agreement								$ 25,000,000

Stockholders' Equity - Stock options and warrants (Details)	6 Months Ended	12 Months Ended
	Jun. 30, 2018 USD ($) $ / shares $ / warrant shares	Dec. 31, 2017 USD ($) $ / shares $ / warrant shares
Warrants, Number of Shares [Roll Forward]
Warrants, Shares, Beginning of Period	209,818
Warrants Granted	0
Warrants Exercised	0
Warrants Canceled	0
Warrants Expired	(161,164)
Warrants, Shares, End of Period	48,654	209,818
Warrants Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price, Warrants Outstanding, Beginning of Period \| $ / warrant	53.20
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 0.00
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	0.00
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	0.00
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 50.30
Weighted Average Exercise Price, Warrants Outstanding, End of Period \| $ / warrant	59.84	53.20
Weighted Average Remaining Contractual Term, Warrant outstanding	2 years 11 months 12 days	11 months 12 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 17,400	$ 0
Warrants, vested and expected to vest	48,654
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	59.84
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	2 years 11 months 12 days
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 17,400
Warrants, Vested. Number	48,654
Warrants, Vested, Weighted Average Exercise Price \| $ / warrant	59.84
Warrants, Vested, Weighted Average Remaining Contractual Term	2 years 11 months 12 days
Warrants, Vested, Aggregate Intrinsic Value \| $	$ 17,400
US Equity Plan [Member]
Options, Outstanding [Roll Forward]
Options, Outstanding, Beginning of Period	1,072,499
Options, Grants in Period, Net of Forfeitures	144,310
Options, Exercises in Period	(74,622)
Options, Forfeitures in Period	(3,030)
Options, Expirations in Period	(65,941)
Options, Outstanding, End of Period	1,073,216	1,072,499
Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options, Outstanding, Weighted Average Exercise Price, Beginning of Period \| $ / shares	$ 33.50
Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	3.80
Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	4.60
Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	3.80
Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	24.50
Options, Outstanding, Weighted Average Exercise Price, End of Period \| $ / shares	$ 31.50	$ 33.50
Options, Outstanding, Weighted Average Remaining Contractual Term	5 years 5 months 1 day	4 years 9 months 4 days
Options, Outstanding, Intrinsic Value \| $	$ 1,237,500	$ 100
Options, Vested and Expected to Vest, Outstanding, Number	1,061,160
Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 31.80
Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	5 years 4 months 13 days
Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 1,205,700
Options, Vested and Expected to Vest, Exercisable, Number	963,497
Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 34.60
Options, Vested, Weighted Average Remaining Contractual Term	4 years 11 months 12 days
Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 950,500

Stockholders' Equity - Restricted Stock (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Equity [Abstract]
Number of restricted stock issued	127,688	132,726
Value of restricted stock issued	$ 351	$ 470

- Share-Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended
- Share-Based Compensation (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 1,968,000	$ 2,175,000	$ 2,115,000	$ 2,708,000
Accelerated equity compensation cost		1,900,000
Modification incremental compensation cost		300,000
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 259,000		$ 259,000
Expected weighted-average period in years of compensation cost to be recognized			2 years 2 months 9 days
Total fair value of shares vested			$ 85,000	5,002,000
Weighted average estimated fair value of shares granted	$ 2.41		$ 2.41		$ 1.72
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 0		$ 0
Expected weighted-average period in years of compensation cost to be recognized			0 years
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	341,000	162,000	$ 381,000	208,000
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1,627,000	1,262,000	1,734,000	1,611,000
Discontinued Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0	$ 751,000	$ 0	$ 889,000

Research Funding (Details) - USD ($) $ in Millions	1 Months Ended		3 Months Ended		6 Months Ended
Research Funding (Details) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	May 31, 2017	Feb. 28, 2017
Deferred Revenue Arrangement [Line Items]
Grants receivable	$ 8.6						$ 12.2
Grants receivable, current						$ 5.7
Revenue from grants	$ 0.3	$ 1.9			$ 7.9
Amortization of deferred credit			$ 0.6	$ 0.3	1.3
Accrued Liabilities [Member]
Deferred Revenue Arrangement [Line Items]
Deferred grant revenue			2.6		2.6
Other Long-Term Liabilities [Member]
Deferred Revenue Arrangement [Line Items]
Deferred grant revenue			$ 2.8		$ 2.8

Income Taxes - Net Operating Loss Carry Forward (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Market capitalization used in net operating loss analysis		$ 124.5
Annual limitation on usage of net operating losses	$ 3.0
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards		$ 210.3

Discontinued Operations - PCT Segment Narrative (Details) - PCT Segment [Member] - Discontinued Operations [Member] - USD ($) $ in Thousands			1 Months Ended
	May 18, 2018	May 18, 2017	May 31, 2018	Jul. 31, 2017	Jun. 30, 2017	Mar. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Subsidiary, Ownership Interest by Parent		80.10%
Transaction Costs Related to Sale		$ 6,919
Payments to Employees		4,300
Retention Payments, First Retention Payment, Percent					50.00%
Retention Payments, Second Retention Payment, Percent	50.00%		50.00%
Hitachi Chemical Co., LTD [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase agreement, additional consideration		4,400
Purchase Agreement, Potential Future Milestone Payment		5,000
Cumulative Revenue Threshold for Receiving Milestone Payment		125,000
Proceeds From Licensing Agreements, Initial Payment						$ 5,000
Proceeds From Licensing Agreements, Closing Payments		65,000		$ 4,400
Proceeds From Licensing Agreements, Escrow Amount		5,000
PCT Allendale, LLC [Member] \| Hitachi Chemical Co., LTD [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase agreement, aggregate purchase price		$ 75,000

Discontinued Operations - Gain on Sale of Discontinued Operation (Details) - PCT Segment [Member] - Discontinued Operations [Member] - USD ($) $ in Thousands		3 Months Ended	6 Months Ended
	May 18, 2017	Jun. 30, 2017	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Fair value of consideration received	$ 79,425
Transaction and retention costs	(6,919)
Carrying value of segment non-controlling interest	3,687
Total consideration net of transaction costs and adjustments	76,193
Less carrying amount of assets and liabilities sold:
Cash	6,727
Accounts receivable	3,702
Deferred costs	4,685
Prepaid expenses and other current assets	743
Property, plant and equipment, net	14,900
Goodwill	7,013
Intangibles, net	2,090
Other assets	215
Accounts payable	(2,278)
Accrued liabilities	(2,927)
Due from Caladrius	450
Unearned revenues	(10,529)
Notes payable	(342)
Disposal group, including discontinued operation, net assets	24,449
Gain on sale of PCT Segment	$ 51,744	$ 51,744	$ 51,744

Discontinued Operations - Operating Results of PCT Segment (Details) - USD ($)		3 Months Ended		6 Months Ended
	May 18, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations		$ 0	$ 40,487,438	$ 0	$ 37,329,963
PCT Segment [Member] \| Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue			5,729,000		16,039,000
Cost of revenues			(5,268,000)		(15,321,000)
Research and development			(143,000)		(257,000)
Selling, general, and administrative			(8,000)		(3,251,000)
Other expense			(8,000)		(16,000)
Provision for income taxes			(11,559,000)		(11,608,000)
Gain on sale of PCT Segment	$ 51,744,000		51,744,000		51,744,000
Income from discontinued operations			$ 40,487,000		$ 37,330,000

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Operating Leases, Future Minimum Payments Due [Abstract]
2018	$ 448		$ 448
2019	906		906
2020	829		829
2021	476		476
2022 and thereafter	130		130
Total minimum lease payments	2,789		2,789
Operating lease expense	$ 200	$ 400	$ 500	$ 700

Subsequent Events (Details) - H.C. Wainwright Sales Agreement [Member] - USD ($)	Aug. 09, 2018	Jun. 30, 2018	Feb. 28, 2018
Subsequent Event [Line Items]
Aggregate offering amount authorized per agreement		$ 12,000,000	$ 12,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate offering amount authorized per agreement	$ 25,000,000